DrugPatentWatch Database Preview
THEOCHRON Drug Patent Profile
Email this page to a colleague
Which patents cover Theochron, and what generic alternatives are available?
Theochron is a drug marketed by Nostrum Pharms Llc and is included in one NDA.
The generic ingredient in THEOCHRON is theophylline. There are thirty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Theochron
A generic version of THEOCHRON was approved as theophylline by RHODES PHARMS on September 1st, 1982.
Summary for THEOCHRON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 140 |
| Patent Applications: | 5,375 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | THEOCHRON at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for THEOCHRON
US Patents and Regulatory Information for THEOCHRON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nostrum Pharms Llc | THEOCHRON | theophylline | TABLET, EXTENDED RELEASE;ORAL | 087400-003 | Feb 21, 1985 | AB | RX | No | No | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ⤷ Free Forever Trial | |||
| Nostrum Pharms Llc | THEOCHRON | theophylline | TABLET, EXTENDED RELEASE;ORAL | 087400-004 | Feb 21, 1985 | AB | RX | No | No | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ⤷ Free Forever Trial | |||
| Nostrum Pharms Llc | THEOCHRON | theophylline | TABLET, EXTENDED RELEASE;ORAL | 087400-002 | Jan 11, 1983 | DISCN | No | No | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
